| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 170.61 mm | 170.61 mm | 170.61 mm | 170.61 mm | 170.61 mm | 170.61 mm |
| Cash burn (monthly) | 2.67 mm | (no burn) | 11.02 mm | 9.54 mm | 6.77 mm | 6.80 mm |
| Cash used (since last report) | 13.85 mm | n/a | 57.19 mm | 49.54 mm | 35.17 mm | 35.28 mm |
| Cash remaining | 156.75 mm | n/a | 113.42 mm | 121.07 mm | 135.44 mm | 135.33 mm |
| Runway (months of cash) | 58.7 | n/a | 10.3 | 12.7 | 20.0 | 19.9 |
| 13F holders | Current |
|---|---|
| Total holders | 124 |
| Opened positions | 21 |
| Closed positions | 44 |
| Increased positions | 48 |
| Reduced positions | 36 |
| 13F shares | Current |
|---|---|
| Total value | 204.98 bn |
| Total shares | 62.98 mm |
| Total puts | 109.70 k |
| Total calls | 201.60 k |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Jennison Associates | 5.63 mm | $26.59 bn |
| BlackRock | 4.79 mm | $22.63 bn |
| Fred Alger Management | 4.12 mm | $19.44 bn |
| Alger Associates | 4.12 mm | $15.61 mm |
| T. Rowe Price Investment Management | 3.67 mm | $17.34 mm |
| Adage Capital Management | 3.63 mm | $13.78 mm |
| Adage Capital Partners GP, L.L.C. | 3.04 mm | $14.33 bn |
| Bain Capital Life Sciences Investors | 2.76 mm | $13.03 bn |
| Bain Capital Life Sciences Opportunities III | 2.76 mm | $16.04 mm |
| Vanguard | 2.55 mm | $12.05 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Mar 25 | Steven Nichtberger | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 450,000 | 751.50 k | 450,000 |
| 3 Mar 25 | David J. Chang | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 145,000 | 242.15 k | 145,000 |
| 3 Mar 25 | Anup Marda | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 145,000 | 242.15 k | 145,000 |
| 3 Mar 25 | Gwendolyn Binder | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 145,000 | 242.15 k | 145,000 |
| 3 Mar 25 | Michael Gerard | Stock Option Common Stock | Grant | Acquire A | No | No | 1.67 | 115,000 | 192.05 k | 115,000 |
